Krystal Biotech is the lead sponsor of 12 current clinical trials in our USA and EU (CTIS) registers. 9 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are KB707, Docetaxel and Pembrolizumab. The most-studied condition is Dystrophic Epidermolysis Bullosa.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497 · Cancer, Melanoma Stage III, Melanoma Stage IV
Drugs: KB707, Pembrolizumab |
Phase 1/2 | Recruiting | 2023-10 | USA |
|
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
NCT06563414 · Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
|
Observational | Recruiting | 2024-08 | USA |
|
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult
|
Phase 1/2 | Recruiting | 2024-04 | USA |
|
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
NCT06999733 · ClinicalTrials.gov ↗ · Neurotrophic Keratitis
|
Phase 1/2 | Recruiting | 2025-07 | USA |
|
Long-Term Follow-up Protocol
NCT04917887 · ClinicalTrials.gov ↗ · Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
|
Observational | Recruiting | 2021-05 | USA |
|
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
NCT07016750 · ClinicalTrials.gov ↗ · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
|
Phase 3 | Recruiting | 2025-06 | USA |
|
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
NCT06049082 · ClinicalTrials.gov ↗ · Alpha 1-Antitrypsin Deficiency
|
Phase 1 | Recruiting | 2024-02 | USA |
|
A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease
NCT07717346 · ClinicalTrials.gov ↗ · Hailey Hailey Disease, Skin Diseases, Lesion Skin
|
Phase EARLY_PHASE1 | Recruiting | 2026-05 | USA |
|
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
NCT05504837 · ClinicalTrials.gov ↗ · Cystic Fibrosis
|
Phase 1 | Recruiting | 2023-06 | USA |
|
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
NCT04540900 · ClinicalTrials.gov ↗ · Skin Roughness, Wrinkle, Fine Lines
|
Phase 1 | Active, closed | 2020-10 | USA |
|
A Study Assessing KB304 for the Treatment of Wrinkles in Women
NCT06724900 · ClinicalTrials.gov ↗ · Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles
|
Phase 1/2 | Active, closed | 2024-11 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Krystal Biotech as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
2025-522723-98-00 · CTIS ↗ · Neoplasms
|
Phase 1 | Authorised | France, Spain |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 11 | 9 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
Krystal Biotech is the lead sponsor of 11 current trials on ClinicalTrials.gov in our USA register, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 9 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 3 drugs and biologicals as interventions. The most frequent are KB707 (3), Docetaxel (2) and Pembrolizumab (2). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.